Mupirocin
drugOn this page
Also known as BactodermBactrobanBRL 4910ABRL-4910ACentanyMupirocinaMupirocineNSC-759182Pseudomonic acidTrans-pseudomonic acidTurixinMurpirocinSID47193668SID50111691Monic acid A3SID144205736C0164508Pseudomonic acid A
Summary
Mupirocin (CHEMBL719) is an approved small-molecule antibacterial drug (ATC D06AX09); indicated across 12 conditions including impetigo and staphylococcus aureus infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D06AX09 (+1 more)
- Indications: 12 conditions
- Clinical trials: 52
- Chemistry: 500.6 Da · C26H44O9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL719 |
| Name | Mupirocin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 446596 |
| ChEBI | CHEBI:7025 |
| ATC | D06AX09, R01AX06 |
| Molecular formula | C26H44O9 |
| Molecular weight | 500.6 |
| InChIKey | MINDHVHHQZYEEK-HBBNESRFSA-N |
SMILES: C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O
IUPAC name: 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
ChEBI definition: An α,β-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.
Pharmacological roles (ChEBI): antibacterial drug, protein synthesis inhibitor.
Other ChEBI roles (chemical / environmental): bacterial metabolite.
Also known as: Bactoderm, Bactroban, BRL 4910A, BRL-4910A, Centany, Mupirocin, Mupirocina, Mupirocine, NSC-759182, Pseudomonic acid, Trans-pseudomonic acid, Turixin
Parent form; salt/anhydrous children: CHEMBL2068726, CHEMBL3989715
Patent coverage: 6,684 distinct patent families (24,662 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| Plasmodium falciparum isoleucyl-tRNA synthetase | 7.24 |
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Streptokinase A, 5-hydroxytryptamine receptor 2A, Isoleucine–tRNA ligase, cytoplasmic, Isoleucine–tRNA ligase, Isoleucine–tRNA ligase.
Bioactivity
ChEMBL activities: 7 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| IARS1 | 9.1 | IC50 | 0.8 | nM | CHEMBL_ACT_368377 |
| P00956 | 8.6 | Ki | 2.5 | nM | CHEMBL_ACT_7934812 |
| P56690 | 7.22 | Ki | 60 | nM | CHEMBL_ACT_16761091 |
| P56690 | 6.6 | Ki | 250 | nM | CHEMBL_ACT_16761092 |
| P10520 | 6.37 | EC50 | 423 | nM | CHEMBL_ACT_5006828 |
| P56690 | 5.64 | Ki | 2310 | nM | CHEMBL_ACT_16761090 |
| P56690 | 5.56 | Ki | 2730 | nM | CHEMBL_ACT_16761088 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
12 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| impetigo | 4 | MONDO:0004592 | EFO:1000714 |
| staphylococcus aureus infection | 3 | MONDO:0005545 | EFO:0005681 |
| hereditary hemorrhagic telangiectasia | 3 | MONDO:0019180 | MONDO:0019180 |
| hemangioma | 2 | MONDO:0006500 | EFO:1000635 |
| radiodermatitis | 2 | MONDO:0043771 | MONDO:0043771 |
| cystic fibrosis | 2 | MONDO:0009061 | MONDO:0009061 |
| sinusitis | 1 | MONDO:0005961 | EFO:0007486 |
| osteomyelitis | 0 | MONDO:0005246 | EFO:0003102 |
| bacterial infectious disease | 0 | MONDO:0005113 | EFO:0000771 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 52.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 19 |
| PHASE4 | 16 |
| PHASE3 | 6 |
| PHASE2 | 4 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06633588 | PHASE4 | RECRUITING | Decolonization Efficacy of Polyhexanide vs. Mupirocin |
| NCT00156377 | PHASE4 | COMPLETED | Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections |
| NCT00179959 | PHASE4 | COMPLETED | The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis |
| NCT00400595 | PHASE4 | COMPLETED | Use of Ointments in Prevention of Catheter Related Infections in PD |
| NCT00801879 | PHASE4 | COMPLETED | Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection |
| NCT01313182 | PHASE4 | COMPLETED | Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin |
| NCT01400308 | PHASE4 | TERMINATED | Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA) |
| NCT01537783 | PHASE4 | COMPLETED | Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess |
| NCT02029872 | PHASE4 | COMPLETED | Stop Community MRSA Colonization Among Patients |
| NCT02127658 | PHASE4 | TERMINATED | MRSA Eradication and Decolonization in Children |
| NCT02218307 | PHASE4 | COMPLETED | The Use of Antibiotic Sinonasal Rinse After Sinus Surgery |
| NCT02284555 | PHASE4 | COMPLETED | Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment) |
| NCT02547103 | PHASE4 | UNKNOWN | Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection |
| NCT02572791 | PHASE4 | COMPLETED | Staph Household Intervention for Eradication (SHINE) |
| NCT04222699 | PHASE4 | COMPLETED | Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization |
| NCT06210594 | PHASE4 | COMPLETED | Staph Intervention for Effective Local Defense |
| NCT07142408 | PHASE3 | RECRUITING | The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal |
| NCT00560599 | PHASE3 | COMPLETED | A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection |
| NCT01949935 | PHASE3 | COMPLETED | Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting |
| NCT02963129 | PHASE3 | UNKNOWN | Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT |
| NCT03883828 | PHASE2/PHASE3 | COMPLETED | Bacterial Decolonization to Prevent Radiation Dermatitis |
| NCT04287777 | PHASE3 | COMPLETED | Safety and Efficacy of Mupirocin Gel in Children With Impetigo |
| NCT05874219 | PHASE2/PHASE3 | COMPLETED | Mupirocin 2% Ointment Vs Spray Antibiotics on Temporary Hemodialysis Catheter |
| NCT05893810 | PHASE3 | UNKNOWN | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis |
| NCT01349192 | PHASE2 | TERMINATED | Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) |
| NCT01408056 | PHASE2 | WITHDRAWN | Timolol Option for Ulcerated Hemangiomas (TOUCH Trial) |
| NCT02967432 | PHASE2 | COMPLETED | Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU |
| NCT03489629 | PHASE2 | COMPLETED | STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) |
| NCT03673956 | PHASE1/PHASE2 | COMPLETED | Topical Antibiotics in Chronic Rhinosinusitis |
| NCT06368856 | PHASE1 | ACTIVE_NOT_RECRUITING | Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study |
| NCT01876550 | PHASE1 | COMPLETED | A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions. |
| NCT01943136 | PHASE1 | UNKNOWN | The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial |
| NCT06046937 | EARLY_PHASE1 | COMPLETED | Monolaurin Ointment Versus Mupirocin Ointment |
| NCT06541145 | Not specified | RECRUITING | Bacterial Decolonization Within Dyads |
| NCT00289588 | Not specified | COMPLETED | An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers |
| NCT00406913 | Not specified | COMPLETED | Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery |
| NCT00513799 | Not specified | COMPLETED | The Natural History of Community-Associated MRSA Infections and Decolonization Strategies |
| NCT01049438 | Not specified | COMPLETED | A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections |
| NCT01152593 | Not specified | UNKNOWN | Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections |
| NCT01153828 | Not specified | COMPLETED | EU PV for Retapamulin-Prescribing |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).